Ann Surg Oncol (2018) 25:1807–1813 https://doi.org/10.1245/s10434-018-6376-y CO NTINU I NG EDU C A T IO N– MELA NO MA S Danielle M. Bello, MD and Charlotte E. Ariyan, MD, PhD Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY INTRODUCTION the adjuvant treatment; (3) personal and ﬁnancial cost; and (4) salvage options that exist. Melanoma is an aggressive form of cutaneous malig- In melanoma, the risk of recurrence is usually estimated nancy, with over 10,000 deaths in the US in 2016. In the after the initial staging operation, which identiﬁes the past 10 years, treatment for stage IV disease with targeted important prognostic clinical and pathologic factors. therapy and immune therapy has changed the trajectory of Online calculators are available to help estimate risk over the disease. While the median survival of patients with time, including melanomacalculator.com, cancermath.net stage IV disease was historically \ 1 year, there are now (which was developed by the Laboratory of Quantitative patients alive without disease recurrence for more than Medicine of Massachusetts General Hospital), or 10 years. The successful treatment of stage IV patients melanomaprognosis.net (which was developed by the raises the question as to whether patients with high-risk American Joint
Annals of Surgical Oncology – Springer Journals
Published: Feb 21, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera